Skip to main content

Branded

  • Sanofi Pasteur begins shipping Fluzone in U.S. for 2012-2013 season

    SWIFTWATER, Pa. — Sanofi Pasteur has begun shipping the first lots of its influenza vaccine for the 2012-2013 season.

  • Vitamin D deficiency associated with poor lung function in child asthmatics

    NEW YORK — Vitamin D deficiency is associated with poor lung function in asthmatic children treated with inhaled corticosteroids, according to a new study from researchers in Boston released Friday.

  • FDA approves generic emergency contraceptive

    PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic contraceptive made by Watson Pharmaceuticals, the drug maker said Friday.

    Watson announced the approval of Next Choice One Dose (levonorgestrel) tablets in the 1.5-mg strength. The drug is an emergency contraceptive used to prevent pregnancy following unprotected sex or contraceptive failure.

    The drug is a generic version of Teva Women's Health's Plan B One-Step, which had sales of about $88 million during the 12-month period ended in March, according to IMS Health.

  • PhRMA: More than 100 drugs under development for mental illnesses

    WASHINGTON — Nearly 200 drugs for mental illnesses are under clinical development or under review by the Food and Drug Administration, the largest trade group for the drug industry said Thursday.

    The Pharmaceutical Research and Manufacturers of America released a report listing 187 drugs, including 52 for depression, 37 for schizophrenia and 26 for anxiety disorders.

  • GSK, Theravance submit investigational COPD treatment to FDA for review

    LONDON and SOUTH SAN FRANCISCO, Calif. — GlaxoSmithKline and Theravance submitted a regulatory application to the Food and Drug Administration for their chronic obstructive pulmonary disease treatment.

  • Lilly announces negative results in schizophrenia drug trial

    INDIANAPOLIS — A clinical trial of a drug for schizophrenia did not yield the desired results, the drug's developer said.

    Eli Lilly announced results of the H8Y-MC-HBBM study of pomaglumetad methionil, for patients with acute exacerbation of schizophrenia. The company said results did not show the drug produced a significantly different effect from the placebo.

  • Obama signs PDUFA reauthorization

    WASHINGTON — President Barack Obama signed into law Monday what some called a "historic" reauthorization of the Prescription Drug User Fee Act.

  • FDA approves Lilly, BMS drug for KRAS wild-type colorectal cancer

    NEW YORK — The Food and Drug Administration has approved a drug made by Eli Lilly and Bristol-Myers Squibb for treating a form of colorectal cancer, the two companies said.

    Lilly and Bristol announced the approval of Erbitux (cetuximab) for treating colorectal cancer that is KRAS mutation-negative, expresses the epidermal growth factor receptor and has spread to other parts of the body, also known as metastasis. The drug is approved for use alongside a chemotherapy combination containing irinotecan, 5-fluorouracil and leucovorin, also known as FOLFIRI.

X
This ad will auto-close in 10 seconds